Clinical trials: Macular Degeneration Choroidal Neovascularization
Choroidal Neovascularization, Age Related Macular Degeneration
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
This investigator initiated pilot study is designed to investigate the efficacy and safety of SD-OCT-guided intravitreal ranibizumab treatment in choroidal neovascularization (CNV) due to myopia.
- Trial name
- NCT03409250
- Testing
- Ranibizumab, Lucentis
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vista Klinik
Macular Degeneration Choroidal Neovascularization
Deep Learning Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) in NVC
To evaluate the activity of neovascular macula degeneretion as assessed by SD-OCTand OCT-A using a split-person study design and deep-learning quantification.
- Trial name
- OCTA (NCT05969418)
- Testing
- Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Federico II University
Choroidal Neovascularization (CNV)
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
- Trial name
- NCT01840410
- Testing
- Ranibizumab
- Where
- 59 sites in Australia, Canada and 19 more
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Myopia, Choroidal Neovascularization
Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia
The purpose of this study is to determine the efficacy and safety of intravitreal injections of bevacizumab in High Myopia´s choroidal neovascularization versus the standard treatment of Photodynamic therapy.
- Trial name
- NCT00967850
- Testing
- Intravitreal Injection, Photodynamic Therapy (Visudyne)
- Where
- 7 sites in Spain
- Volunteers
- 56 people
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Age-Related Macular Degeneration, Choroidal Neovascularization
Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD
The goals of this study are: To assess the impact of genetic testing based on how it alters behaviors, to assess the utility of serum biomarker measurement in combination with genetic testing, to assess the utility of genetic…
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization, Genetic Counseling
- Trial name
- NCT03024424
- Testing
- Early disclosure, Late disclosure
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Utah
Uveitis, Diabetic Retinopathy
Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study
Direct intravitreal administration of medication is the preferred method of treatment for uveitis and retinal vascular disorders.
- Conditions
- Uveitis, Diabetic Retinopathy, Choroidal Neovascularization
- Trial name
- ADA01 (NCT00855608)
- Testing
- adalimumab
- Where
- Lebanon
- Volunteers
- 15 people
- Sponsor
- Rafic Hariri University Hospital
Age Related Macular Degeneration
Usage of the Home Macular Perimeter (HMP)
Demonstrate the ability of the current interactive tutorial and 1-800 support to teach an AMD patient to use the HMP device.
- Trial name
- HMP (NCT00596388)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Notal Vision Ltd.
Macular Degeneration, Maculopathy, Age-Related
Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative…
- Conditions
- Macular Degeneration, Maculopathy, Age-Related, Age-Related Maculopathies, Age-Related Maculopathy
- Trial name
- NCT00051129
- Testing
- Anecortave Acetate 15 mg sterile suspension, Anecortave Acetate Vehicle
- Volunteers
- 291 people
- Sponsor
- Alcon Research
Macular Degeneration, Choroidal Neovascularization
Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD
The objectives of this study are to evaluate the safety(first objective) and efficacy(second objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age related Macular Degeneration (AMD).
- Trial name
- NCT01021956
- Testing
- STAKEL
- Where
- 4 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- Steba Biotech S.A.
AMD, Wet AMD
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.
- Conditions
- AMD, Wet AMD, Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
- Trial name
- INTREPID (NCT01016873)
- Testing
- IRay
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 230 people
- Sponsor
- Oraya Therapeutics, Inc.
Wet Macular Degeneration
Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
The addition of an anti-inflammatory agent could be a valid option for controlling choroidal neovascularization, as simply inhibiting VEGF addresses neither the multifactorial pathogenesis of choroidal neovascularization nor the…
- Trial name
- NCT02060604
- Testing
- Ketorolac + Ranibizumab, Ranibizumab
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Università degli Studi di Brescia
Age Related Macular Degeneration
PHP Home Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV)
The primary objective of this study is to assess the ability of the PHP \& HPHP to detect newly diagnosed non treated Chorodial neovascularization (CNV) lesion associate with advanced age related Macular Degeneration (AMD) and…
- Trial name
- NCT00359008
- Where
- Israel
- Volunteers
- 336 people
- Sponsor
- Notal Vision Ltd.
Choroidal Neovascularization, Diabetic Retinopathy
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
This is a two-part study. The first part (Stratum I) is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (PF-04523655) will be given to all patients who participate.
- Conditions
- Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- MATISSE (NCT01445899)
- Testing
- PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II)
- Where
- 51 sites in United States, Belgium and 5 more
- Volunteers
- 258 people
- Sponsor
- Quark Pharmaceuticals
Age Related Macular Degeneration
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable…
- Trial name
- NCT00593450
- Testing
- ranibizumab, bevacizumab
- Where
- 59 sites in United States
- Volunteers
- 1,208 people
- Sponsor
- University of Pennsylvania
Macular Degeneration, Choroidal Neovascularization
Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD
Wet age-related macular degeneration (AMD) is caused by the formation and growth of abnormal blood vessels (angiogenesis) in the retina. The new blood vessels have fragile walls and can leak fluid into the retina.
- Trial name
- NCT00509548
- Testing
- TG100801
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- TargeGen
Choroidal Neovascularization in Angioid Streaks
Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).
Angioid streaks are rare lesions associated to retinal pigment epithelium degenerations. They can be caused by general diseases as pseudoxanthoma elasticum, Paget's disease or drepanocytosis.
- Trial name
- ASTRID (NCT02573038)
- Testing
- Aflibercept
- Sponsor
- Hospices Civils de Lyon
Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV)
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
The purpose of this study is to evaluate the efficacy and safety of the aflibercept 8 mg used in a personalized regimen, with flexible loading dose and treatment intervals from 8 to 24 weeks in eyes with treatment-naive PCV.
- Trial name
- PALLAS (NCT07389980)
- Testing
- aflibercept 8 mg
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yeungnam University College of Medicine
Polypoidal Choroidal Vasculopathy
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
Polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration (NV AMD), is an important cause of central visual loss, especially among Asian and African descendants.
- Trial name
- NCT04707027
- Testing
- Aflibercept Injection (2 mg/0.05 ml), Defer treatment
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Chiang Mai University
Macular Degeneration, Choroidal Neovascularization
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with…
- Trial name
- NCT00433017
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 12 sites in Austria, Belgium and 10 more
- Volunteers
- 255 people
- Sponsor
- Novartis
Choroidal Neovascularization
Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study
Efficacy of monthly intravitreal anti-vascular endothelial growth factor (VEGF) associated to systemic immunosuppression in patients with Vogt-Koyanagi-Harada Disease and choroidal neovascularization. Minimum follow-up 12 months.
- Trial name
- NCT02015351
- Testing
- bevacizumab
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- University of Sao Paulo